The Designed Pore-Forming Antimicrobial Peptide C14R Combines Excellent Activity against the Major Opportunistic Human Pathogen Pseudomonas aeruginosa with Low Cytotoxicity

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 17; no. 1; p. 83
• Main Authors: Mildenberger, Vanessa, Alpízar-Pedraza, Daniel, Martell-Huguet, Ernesto M, Krämer, Markus, Bolotnikov, Grigory, Otero-Gonzalez, Anselmo J, Weil, Tanja, Rodriguez-Alfonso, Armando, Preising, Nico, Ständker, Ludger, Vogel, Verena, Spellerberg, Barbara, Kissmann, Ann-Kathrin, Rosenau, Frank
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 09-01-2024; MDPI
• Subjects: Amino acids; Antimicrobial agents; antimicrobial peptides; Bacteria; clinical isolates; Cytotoxicity; Gram-positive bacteria; Hydrogen bonds; Pathogens; Peptides; pore-formation; Pseudomonas aeruginosa; Simulation; Toxicity; Pseudomonas aeruginosa; clinical isolates; antimicrobial peptides; pore-formation
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph17010083

The diminishing portfolio of mankind's available antibiotics urges science to develop novel potent drugs. Here, we present a peptide fitting the typical blueprint of amphipathic and membrane-active antimicrobial peptides, denominated C14R. This 2 kDa peptide consists of 16 amino acid residues, with seven being either hydrophobic, aromatic, or non-polar, and nine being polar or positively charged, strictly separated on opposite sides of the predicted α-helix. The affinity of the peptide C14R to
membranes and its intrinsic tendency to productively insert into membranes of such composition were analyzed by dynamic simulations. Its biological impact on the viability of two different
reference strains was demonstrated by determining the minimal inhibitory concentrations (MICs), which were found to be in the range of 10-15 µg/mL. C14R's pore-forming capability was verified in a permeabilization assay based on the peptide-triggered uptake of fluorescent dyes into the bacterial cells. Finally, the peptide was used in radial diffusion assays, which are commonly used for susceptibility testing of antimicrobial peptides in clinical microbiology. In comparison to reference strains, six clinical
isolates were clearly affected, thereby paving the way for further in-depth analyses of C14R as a promising new AMP drug in the future.